©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Mar 14, 2026; 32(10): 113771
Published online Mar 14, 2026. doi: 10.3748/wjg.v32.i10.113771
Published online Mar 14, 2026. doi: 10.3748/wjg.v32.i10.113771
Pristimerin ameliorates spasmolytic polypeptide-expressing metaplasia by modulating Cdkn1c (p57)-mediated glycolytic reprogramming
Jun-Song Wen, Zi-Wei Pan, Xue-Dan Yao, Yao-Dong Zhu, Department of Integrated Traditional Chinese and Western Medicine Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China
Yan-Qing Liu, Institute of Traditional Chinese Medicine and Western Medicine, School of Medicine, Yangzhou University, Yangzhou 225000, Jiangsu Province, China
Author contributions: Wen JS, Pan ZW and Zhu YD designed and coordinated the study; Wen JS, Pan ZW, Yao XD and Liu YQ performed the experiments, acquired and analyzed data; Wen JS, Pan ZW, Yao XD, Liu YQ and Zhu YD interpreted the data; Wen JS and Zhu YD wrote the manuscript; Liu YQ and Zhu YD reviewed the manuscript; all authors have read and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. 82274355; and Key Project for the Cultivation of Outstanding Young Teachers in Anhui Province’s Colleges and Universities, No. 2023-385.
Institutional review board statement: The study does not involve any human experiments.
Institutional animal care and use committee statement: All animal experiments strictly complied with ethical standards approved by the Institutional Animal Care and Use Committee of Anhui Medical University (No. LLSC20220294).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: Data supporting the findings of this study are available from the corresponding author
Corresponding author: Yao-Dong Zhu, MD, Chief Physician, Department of Integrated Traditional Chinese and Western Medicine Oncology, First Affiliated Hospital of Anhui Medical University, No. 120 Wanshui Road, High-tech Zone, Hefei 230000, Anhui Province, China. zhuyaodong2022@126.com
Received: September 10, 2025
Revised: October 31, 2025
Accepted: December 16, 2025
Published online: March 14, 2026
Processing time: 174 Days and 20 Hours
Revised: October 31, 2025
Accepted: December 16, 2025
Published online: March 14, 2026
Processing time: 174 Days and 20 Hours
Core Tip
Core Tip: This study systematically investigated the therapeutic effects of the natural compound pristimerin on spasmolytic polypeptide-expressing metaplasia (SPEM) using a high-dose tamoxifen-induced mouse model, tamoxifen-treated human gastric epithelial cells, and N-methyl-N’-nitro-N-nitrosoguanidine/Helicobacter pylori-induced gastric organoids. It elucidated the underlying mechanism by which pristimerin ameliorates SPEM through regulating Cdkn1c (p57) to suppress glycolytic reprogramming. These findings not only provide novel mechanistic insights into pristimerin treatment for SPEM but also offer a crucial theoretical basis for targeting p57 in SPEM therapy.